167 related articles for article (PubMed ID: 28383769)
1. Unleashing the immune response against childhood solid cancers.
Anderson J
Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28383769
[TBL] [Abstract][Full Text] [Related]
2. CARTs for Solid Tumors: Feasible or Infeasible?
Li W; Song X; Jin Y; Li F; Yu H; Cao C; Jiang Q
Oncol Res Treat; 2017; 40(9):540-546. PubMed ID: 28813706
[TBL] [Abstract][Full Text] [Related]
3. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
[TBL] [Abstract][Full Text] [Related]
4. Redirecting T cells to treat solid pediatric cancers.
Rauwolf KK; Rossig C
Cancer Metastasis Rev; 2019 Dec; 38(4):611-624. PubMed ID: 31811551
[TBL] [Abstract][Full Text] [Related]
5. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
Di S; Li Z
Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
7. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
8. Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.
Luo C; Wei J; Han W
Sci China Life Sci; 2016 Apr; 59(4):349-59. PubMed ID: 27009301
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles.
Li K; Lan Y; Wang J; Liu L
Tumour Biol; 2017 Mar; 39(3):1010428317692229. PubMed ID: 28347250
[TBL] [Abstract][Full Text] [Related]
10. CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.
Gilham DE; Debets R; Pule M; Hawkins RE; Abken H
Trends Mol Med; 2012 Jul; 18(7):377-84. PubMed ID: 22613370
[TBL] [Abstract][Full Text] [Related]
11. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
Houot R; Schultz LM; Marabelle A; Kohrt H
Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444
[TBL] [Abstract][Full Text] [Related]
12. Armed T cells with CAR for cancer immunotherapy.
Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):331-2. PubMed ID: 27080712
[No Abstract] [Full Text] [Related]
13. Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors.
Abken H
Immunotherapy; 2015; 7(5):535-44. PubMed ID: 26065478
[TBL] [Abstract][Full Text] [Related]
14. Grafting T cells with tumor specificity: the chimeric receptor strategy for use in immunotherapy of malignant diseases.
Hombach A; Pohl C; Reinhold U; Abken H
Hybridoma; 1999 Feb; 18(1):57-61. PubMed ID: 10211789
[TBL] [Abstract][Full Text] [Related]
15. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
[TBL] [Abstract][Full Text] [Related]
16. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.
Khalil DN; Smith EL; Brentjens RJ; Wolchok JD
Nat Rev Clin Oncol; 2016 May; 13(5):273-90. PubMed ID: 26977780
[TBL] [Abstract][Full Text] [Related]
17. Current status of genetic modification of T cells for cancer treatment.
Dotti G; Heslop HE
Cytotherapy; 2005; 7(3):262-72. PubMed ID: 16081353
[TBL] [Abstract][Full Text] [Related]
18. Engineering T-cells with antibody-based chimeric receptors for effective cancer therapy.
Thistlethwaite F; Mansoor W; Gilham DE; Hawkins RE
Curr Opin Mol Ther; 2005 Feb; 7(1):48-55. PubMed ID: 15732529
[TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects.
Guo Y; Wang Y; Han W
J Immunol Res; 2016; 2016():3850839. PubMed ID: 26998495
[TBL] [Abstract][Full Text] [Related]
20. Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells.
Alrifai D; Sarker D; Maher J
Immunopharmacol Immunotoxicol; 2016; 38(1):50-60. PubMed ID: 26473647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
